FDA solicits feedback on distracting elements of drug ads

02/6/2012 | Xconomy

The FDA reopened the comment period on its proposed rule for direct-to-consumer marketing of prescription drugs. The decision follows release of an agency-sponsored study that assessed the impact of distracting images or statements in ads on consumers' understanding of information about drug risks and benefits.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL